"This latest move by Eli Lilly demonstrates that these multinational drug companies are working together to prevent U.S. seniors from obtaining safe and affordable medications from Canadian pharmacies," Dave Robertson, president of Calgary's crossborderpharmacy.com said in a statement.
The Toronto Star
October 19, 2003
Drug firm limits sales to Canada
Associated Press
INDIANAPOLIS—Eli Lilly and Co. has begun to limit its drug sales to Canadian pharmacies, joining other drug giants that are trying to prevent their medications from being sold to U.S. consumers from Canada.
The Indianapolis-based drug maker told 24 Canadian drug wholesalers in a letter that it will limit sales of its drugs to amounts Lilly estimates are sufficient to supply the Canadian market.
Starting immediately, if a Canadian wholesaler tries to order more Lilly product than Lilly's estimate of what is appropriate for Canadian use, "they will not be able to have it," Lilly spokesperson Rob Smith said.
Canadian price controls, the cheaper dollar and other factors together mean brand-name prescription drugs sell for 35 per cent to 40 per cent less in Canada than in the United States.
Earlier this year, Pfizer of New York and Britain's GlaxoSmithKline took similar steps to stop sales to U.S. customers.
"This latest move by Eli Lilly demonstrates that these multinational drug companies are working together to prevent U.S. seniors from obtaining safe and affordable medications from Canadian pharmacies," Dave Robertson, president of Calgary's crossborderpharmacy.com said in a statement.
Brought to you by WikidFranchise.org
Risks: Big Pharma, Canada, United States, 20031019 Drug firm
